Abstract. p62 (also known as sequestosome 1) protein, is a small regulatory protein that accumulates in autophagy-defective cells that has been demonstrated to be involved in the prognosis and survival of patients with several types of cancer. However, to the best of our knowledge, there have been no such studies for osteosarcoma (OS). In the present study, the expression of p62 in 70 OS samples was determined using immunohistochemistry and its association with various clinicopathological factors was assessed. The results demonstrated that the overexpression of p62 protein was detected in 77.1% (54/70) samples, and the expression levels were significantly associated with tumor size (P= 0.001), metastasis (P= 0.036), clinical staging (P= 0.003) and poor prognosis (P= 0.0058). Furthermore, suppression of the p62 expression by short hairpin RNA interference in F5M2 and F4 cells lines led to decreased cell proliferation, migration and invasion in vitro. These results suggested that increased expression of p62 may be involved in OS progression, and therefore the excess expression of p62 may serve as a novel prognostic biomarker for patients with OS.
Introduction
Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents, and accounts for ~20% of all primary bone cancer worldwide (1, 2) . Although there have been improvements in surgical and multi-agent chemotherapeutics, the long-term survival rate for patients with non-metastatic OS remains at ~60% (3), whereas, currently, a 5-year survival rate of 30% is observed in patients with metastatic OS (1, 4) . Therefore, it is essential to analyze the biological evidence at the molecular level of OS to identify novel prognostic markers and determine the underlying molecular mechanism of OS metastasis.
p62, also known as sequestosome 1, is a multifunctional scaffold protein that regulates cell proliferation, apoptosis, cell survival, inflammation and tumorigenesis through the catabolism of molecules (5, 6) . The p62 protein is one of the selective substrates of autophagy, localized on the membranes of autophagosomes (7) . It has been identified that the accumulation of the p62 protein is variably associated with different types of tumor, including cancer of the prostate, breast, lung, colon and endometrium (8) (9) (10) (11) (12) ). An excessive expression of p62 has been identified to be a cause of poor prognosis in certain tumor types, including prostate and endometrial cancer (11, 12) . Furthermore, it has been demonstrated that the abnormal expression of p62 may be associated with the activation of oncogenic signaling pathways, including the mammalian target of rapamycin (mTOR), mitogen-activated protein kinase, nuclear factor κB (NF-κB), Wnt/β-catenin and potentially other signaling pathways (7, 13) . Therefore, it is suggested that p62 may function as an oncogene and is involved in poor prognosis in human cancer.
However, the function and clinical significance of p62 has not yet been completely elucidated in OS. In the present study, the expression of p62 was examined and its association with clinicopathological characteristics was investigated in patients with OS.
Materials and methods
Patients and tumor specimens. The present study was approved by the Ethics Committee of Xi'an HongHui Hospital (Xi'an, China). Either the patients or their guardians provided written informed consent for participation in the study. Formalin-fixed paraffin-embedded tissues were obtained from 85 patients with OS who underwent tumor resection at Xi'an Overexpression of p62 is associated with poor prognosis and aggressive phenotypes in osteosarcoma Immunohistochemical analysis. Immunohistochemistry was performed as described in our previous study (16) . The anti-p62 antibody was used at a dilution of 1:100. Images were observed at magnification, x400 under a fluorescence microscope. The final scores of expression of p62 were calculated as described previously (16) . Each specimen was categorized as follows: 0, (0); 1+, (1-3); 2+, (4-8); and 3+, (9) (10) (11) (12) . Scores of 0-3 and 4-12 were designated low and high expression, respectively. The following thermocycling conditions were used: 5 min at 95˚C, followed by 40 cycles of 10 sec at 95˚C and 30 sec at 60˚C. The p62 gene expression was calculated using the 2 -ΔΔCq method (17) . The primers used for amplification were as follows: Human p62 forward, 5'-TGA GGA ACA GAT GGA GTC GG-3' and reverse, 5'-GAG ATG TGG GTA CAA GGC AG-3'; human GAPDH forward, 5'-ACC CAC TCC TCC ACC TTT G-3' and reverse, 5'-CAC CAC CCT GTT GCT GTA G-3'. All experiments were performed in triplicate and repeated at least three times independently.
Cell counting kit-8 (CCK-8) assay.
F5M2-shp62, GFP-F5M2, F4-shp62 and GFP-F4 cells were seeded into 96-well plates at a density of 2,000 cells/well. After 24 h of incubation at 37˚C in 5% CO 2 , 10 µl/well CCK-8 reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added to one plate, which was incubated for 2 h at 37˚C and measured using a microplate reader (Thermo Fisher Scientific, Inc.) at 490 nm. Each experiment was repeated three times independently.
Transwell migration and invasion assays. The Transwell migration and invasion assays were performed as in our previous study (18) . The migratory and invasive potential of cells were assessed using a Transwell (Corning Inc., Corning, NY, USA) inserts only or using inserts pre-coated with 50 µl of BD Matrigel™ Basement Membrane Matrix (1:3 dilution, BD Biosciences, Franklin Lakes, NJ, USA). The upper chambers were seeded with 1x10 4 cells suspended in serum-free RPMI-1640 medium, and the lower chambers were filled with complete RPMI-1640 medium with 10% FBS (0.6 ml/well). The invasion was evaluated after 16 h of incubation at 37˚C. The migration was assessed after 24 h of incubation. Invasion and migration were examined under a light microscope (Nikon Eclipse 80i; Nikon Corporation, Tokyo, Japan) at a magnification, x200 in five randomized fields. All experiments were independently repeated three times.
Western blot analysis. Cellular lysates were prepared in chilled radioimmunoprecipitation assay lysis buffer (Cell Signaling Technology, Inc.), and the protein concentrations were determined using a BCA protein assay kit (Pierce; Thermo Fisher Scientific, Inc.). Proteins (10 µl) were loaded and separated by electrophoresis on 10% SDS-polyacrylamide gels at 110 V for 2 h. Following electrophoresis, the SDS-PAGE gels were transferred electronically to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). PVDF membranes were blocked using a solution containing 5% skimmed milk and incubated overnight at 4˚C with the following antibodies: Anti-p62 and anti-β-actin (1:1,000). Following washing with Tris-buffered saline with Tween-20, the membranes were incubated for 1 h at room temperature with HRP-conjugated goat anti-rabbit immunoglobulin and monoclonal antibodies against β-actin. Reactive proteins were visualized using an Immobilon western horseradish peroxidase chemiluminescence kit (EMD Millipore, Billerica, MA, USA). Relative p62 expression levels as analyzed using ImageJ software version 1.47 (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis. The statistical analyses were carried out using GraphPad Prism software (version 5.0; GraphPad Software Inc., La Jolla, CA, USA). The immunohistochemistry data were analyzed using the χ 2 test. Survival data were analyzed using the Kaplan-Meier with log-rank tests estimator method. The RT-qPCR, western blot analysis, inhibitor migration assay and inhibitor invasion assay results were analyzed by one-way analysis of variance. All other data were analyzed using a two-sided Student's t-test. The data are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.
Results
Clinicopathological features and prognostic implications of p62 expression. Using immunohistochemistry, it was identified that the p62 was distributed in the cytoplasm and perinuclear membrane of the OS cells (Fig. 1A and B) . Compared with osteochondroma samples, the expression rate of p62 was significantly increased in OS (Table I; Fig. 1C ). The increased expression of p62 protein was observed in 54/70 samples (77.14%) and was identified to be significantly associated with tumor size (P= 0.001), metastasis (P= 0.036) and clinical staging (P=0.003) (Table II) . These patients were also significantly associated with a decreased overall survival time (P=0.0058; Fig. 1D ).
Human OS cell lines F5M2 and F4 express p62. RT-qPCR results identified that the expression level of p62 mRNA was highest in the human OS cell lines F5M2 and F4 and lowest in the human osteoblastic cell line hFOB1.19 (P<0.001; Fig. 2A ). The expression level of p62 protein in these cell lines was then assessed by western blotting. The results demonstrated that OS cells (F5M2 and F4) expressed increased levels of p62 protein compared with osteoblastic cells (hFOB1.19) (Fig. 2B) , which was identified to be a significant difference (Fig. 2C) .
p62 knockdown decreases the proliferative capacity of F5M2 and F4 cells.
A CCK-8 cell proliferation assay was used to examine the effect of p62 inhibition on the in vitro proliferative capacity of F5M2 and F4 cells. p62 expression was stably downregulated by lentiviral-mediated shRNA. Compared with the controls (GFP-F5M2 and GFP-F4), the p62 expression was efficiently decreased in the stable p62-inhibited cells (F5M2-shp62 and F4-shp62) (Fig. 2D) , which was identified to be a significant difference (Fig. 2E) . Subsequently, the CCK-8 cell proliferation assay demonstrated that stable p62 knockdown decreased the proliferation of F5M2 (P<0.01; Fig. 3A ) Table I . Expression levels of p62 in osteosarcoma and osteochondroma specimens. Table II . Association between p62 expression and clinicopathological data in patients with osteosarcoma. 
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Discussion
The results of the present study demonstrated that the increased expression of p62 protein was significantly associated with tumor size, metastasis and clinical staging in human OS, and may be used as a prognostic factor. However, patients with increased expression of p62 protein were identified to be significantly associated with decreased overall survival times compared with those with low p62 expression. To the best of our knowledge, this present study is the first to investigate the clinical significance of p62 expression in OS. The abnormal expression of p62 detected in a variety of tumors, including breast, prostate, lung, liver and oral cancer, serves an active function in tumorigenesis and metastasis (12, 19, 20) . To determine the p62 protein levels in prostate cancer, Burdelski et al (11) used immunohistochemistry to assess 7,822 prostate cancers and found that p62 stained in 73% (5,716/7,822) . In addition, the protein was markedly associated with high Gleason grade, positive nodal status, advanced pathological tumor stage and positive resection margin (12) . Therefore, the accumulation of p62 may be considered as a predictor of the detrimental prognostic behavior of prostate cancer (12) . The expression of p62 is substantially weak in normal gastric tissue samples, whereas increased cytoplasmic and nuclear levels are detected in gastric cancer (21) . The immunohistochemical analysis of the present study indicated increased expression p62 protein in 77.14% (54/70) of the analyzed OS samples.
Previous studies have demonstrated that the autophagy system constantly degraded the p62 protein (22, 23) , whereas other studies indicated that p62 expression is regulated at the transcriptional level (24, 25) . However, the specific function of p62 in tumors remains unclear, and it has been demonstrated that increased p62 mRNA expression is associated with increased p62 protein expression in the oral squamous cell carcinoma (19) . In the present study, it was demonstrated that the p62 mRNA and protein levels were upregulated in human F5M2 and F4 OS cells, suggesting that the protein regulation occurred at the transcriptional and translational levels.
In order to investigate the function of p62 in tumor cell proliferation, migration and invasion, stable p62 knockdown cell lines were established using specific shRNA. Using a CCK-8 assay, p62 knockdown was determined to suppress the proliferation of F5M2 and F4 OS cells. Furthermore, the migration and invasion assays demonstrated that p62 knockdown decreased the migration and invasion of F5M2 and F4 cells in vitro. Thus, increased p62 expression increased the proliferation, migration and invasion of OS cells in vitro. Previous studies have also established that the p62 protein functions as a hub for various signal transduction pathways for cell survival and cell death (20) . The overexpression of p62 has been identified to promote tumor cell survival via impairment of the NF-κB signaling pathway (26) . The NRF2-Keap1 pathway consisted of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2), and the cytoplasmic contact protein Keap1. NRF2 is a central regulator of the cellular antioxidant stress reaction. Furthermore, NRF2 is able to regulate the expression of several detoxification enzymes and a series of antioxidative protein genes, thereby serving a major function in antitumor mechanisms (6) . Under normal conditions, NRF2 was degraded by the ubiquitin-proteasome pathway through interaction with Keap1. When exposed to the pro-electronic reagent, reactive oxygen species and nitric oxide, Keap1 is activated, leading to NRF2 heterodimerization and translocation to the nucleus (6) . Subsequently, the nuclear NRF2 is able to induce a series of transcription cell protective genes (6) . The p62 protein is able to directly interact with Keap1 of NRF2, and the excessive expression of p62 is able to continuously stimulate NRF2, which is hypothesized to lead to tumor progression (27) . Aberrant mitosis often leads to tumor occurrence (28) . The active association of cyclin-dependent kinase (CDKs) with cell cycle proteins is the key to an orderly cell cycle (28) . The lack of cell cycle proteins or the presence of CDK inhibitor leads to cell cycle arrest and cell death (29) . The study of Linares et al (30) elucidated the expression of p62 protein in different cells at various stages of the cell cycle, and identified that the protein had been phosphorylated in the early stage of mitosis. Following inhibition of the activity of CDKs, the p62 protein was phosphorylated at Thr 269 and Ser 272 , suggesting that it may be involved in the mitotic division of cells (30) . In addition, it has been demonstrated that p62 is able to activate the mTOR signaling pathway to regulate cell growth and autophagy (31) .
There were several limitations to the present study. First, the study was primarily limited by the number of patient samples. Secondly, despite osteochondroma as the control group, the study lacked normal tissue as the control group. Finally, the regulatory mechanism of p62 in OS was not elucidated. Further studies with larger patient populations involving normal tissue, mechanism of p62 in OS, and animal experiment are essential to assess p62 more accurately as a therapeutic target for OS.
In summary, the results of the present study demonstrated that p62 was upregulated in human OS. Furthermore, the overexpression of p62 protein is associated with poor survival rates in patients with OS. Additionally, p62 may be involved in osteosarcoma progression; however, further studies are a prerequisite for understanding the significance of increased expression of p62 in order to develop specific and comprehensive treatments.
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